Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T,68-Ga PSMA-11
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Convergent Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : 225-Ac Rosopatamab Tetraxetan,177-Lu PSMA-I&T,68-Ga PSMA-11
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Convergent Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PMI21
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Precision Molecular
Deal Size : Undisclosed
Deal Type : Agreement
IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211
Details : Astatine-211 is a high-energy alpha-emitting radioisotope that can have a very powerful therapeutic effect when combined with the right targeting molecule. PMI is developing an astatine-211 labeled inhibitor of prostate-specific membrane antigen (PSMA) k...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : PMI21
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Precision Molecular
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PNT2001,225-Ac
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement
Details : PDS Biotechnology licenses National Cancer Institute for intellectual property related to tumor-associated active T-cell receptor gamma. The administration of PDS0102, Versamune-TARP tumor antigen combination, led to induction of large numbers of tumor t...
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
September 11, 2021
Lead Product(s) : PNT2001,225-Ac
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement